Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06142994
Status:
COMPLETED
Last Update Posted:
2024-06-27
First Post:
2023-11-08
Brief Title:
Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting
Sponsor:
Neopharm Bulgaria Ltd
Organization:
Neopharm Bulgaria Ltd
Study Overview
Official Title:
Phase 4 Efficacy and Safety of Atusin CAP in the Treatment of Subjects With Acute Bronchitis in the Primary Healthcare Setting Prospective Multicenter Double-blind Placebo-controlled Randomized Parallel-arm Clinical Study
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AАBA
Brief Summary:
The study aims to evaluate the effectiveness and safety of Atusin CAP in reducing the severity of acute bronchitis
Detailed Description:
A prospective multicenter double-blind placebo-controlled randomized parallel study will be conducted to evaluate the effect of Atusin CAP on the rapid relief of irritating cough in adults with acute bronchitis treated in actual clinical practices in primary healthcare where patients seek help as a result of serious complaints
The combination of the three extracts a mix of essential oils bromelain and green Brazilian propolis may represent a breakthrough in symptomatic treatment by blocking the triggering mechanisms of cough due to acute bronchitis
The combination of the three extracts a mix of essential oils bromelain and green Brazilian propolis may represent a breakthrough in symptomatic treatment by blocking the triggering mechanisms of cough due to acute bronchitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None